Barclays PLC Raises Holdings in Y-mAbs Therapeutics, Inc.

12 hours ago · Barclays PLC lifted its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 433.4% during the third quarter, according to its most …

4%
OFF

Barclays PLC Raises Holdings In Y-mAbs Therapeutics, Inc.

2 weeks from now

12 hours ago · Barclays PLC lifted its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 433.4% during the third quarter, according to its most …

etfdailynews.com

4%
OFF

Barclays PLC Purchases 56,244 Shares Of Y-mAbs Therapeutics, Inc ...

2 weeks from now

Dec 31, 2024 · Barclays PLC lifted its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 433.4% during the third quarter, according to the company …

defenseworld.net

6%
OFF

Barclays PLC Has $49,000 Stock Position In Y-mAbs Therapeutics, …

2 weeks from now

Dec 29, 2023 · Barclays PLC trimmed its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 84.6% in the 2nd quarter, Holdings Channel reports. The fund owned 7,317 …

americanbankingnews.com

$14
OFF

Y-mAbs Therapeutics Price Target Lowered To $14 From $17 At BofA

2 weeks from now

Jan 7, 2025 · BofA lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $14 from $17 and keeps a Neutral rating on the shares. While political and rate uncertainty continues to …

yahoo.com

$10.26
OFF

Analysts Issue Forecasts For YMAB FY2024 Earnings

2 weeks from now

Dec 10, 2024 · Check Out Our Latest Stock Report on Y-mAbs Therapeutics. Y-mAbs Therapeutics Trading Down 2.7 %. NASDAQ YMAB opened at $10.26 on Monday. The …

etfdailynews.com

56%
OFF

Y-mAbs Therapeutics, Inc. (YMAB) - Yahoo Finance

2 weeks from now

Get the latest Y-mAbs Therapeutics, Inc. (YMAB) stock news and headlines to help you in your trading and investing decisions. ... RPRX Royalty Pharma plc 29.49 +3.29 (+12.56%) Top Losers.

yahoo.com

2%
OFF

Barclays PLC Raises Stock Position In Regulus Therapeutics Inc.

2 weeks from now

6 days ago · Barclays PLC lifted its holdings in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS – Free Report) by 285.2% during the 3rd quarter, Holdings Channel …

etfdailynews.com

FAQs about Barclays PLC Raises Holdings in Y-mAbs Therapeutics, Inc. Coupon?

What's new at Y-mAbs Therapeutics (ymab)?

The latest update is out from Y-Mabs Therapeutics ( (YMAB) ). Y-mAbs Therapeutics announced a strategic business realignment to enhance operational flexibility and accelerate clinical development. The company will establish two business units focusing on radiopharmaceuticals and DANYELZA. ...

Who owns y-mAbs Therapeutics?

Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at approximately $44,000. China Universal Asset Management Co. Ltd. grew its holdings in Y-mAbs Therapeutics by 66.3% during the 3rd quarter. ...

Does Barclays PLC own Regulus Therapeutics Inc?

Barclays PLC lifted its holdings in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS – Free Report) by 285.2% during the 3rd quarter, Holdings Channel reports. The firm owned 84,477 shares of the biopharmaceutical company’s stock after buying an additional 62,549 shares during the period. ...

Will earnings estimate revisions help y-mAbs Therapeutics (ymab) continue moving higher?

Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. We can readily understand why investors are attracted to unprofitable companies. For example, Y-mAbs Therapeutics... ...

How do I receive news & ratings for Y-mAbs Therapeutics?

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. ...

Does China universal asset management own y-mAbs Therapeutics?

China Universal Asset Management Co. Ltd. grew its holdings in Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after acquiring an additional 3,416 shares during the last quarter. ...